Search results for "Lymphatic"

showing 10 items of 1179 documents

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Ita…

2005

Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4-12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%-62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previou…

AdultMaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyLung NeoplasmsOrganoplatinum CompoundsColorectal cancerPhases of clinical researchAntineoplastic AgentsToxicologyDeoxycytidineGastroenterologyDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansPharmacology (medical)CapecitabinePeritoneal NeoplasmsAgedAged 80 and overPharmacologyPerformance statusbusiness.industryCarcinomaLiver NeoplasmsMiddle Agedmedicine.diseaseOxaliplatinSurgeryOxaliplatinRegimenItalyOncologyFluorouracilLymphatic MetastasisFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres

1995

Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE-CytaBOM, two with MACOP-B, one with CHOP and one with LSA2-L2. As of November 1990, all newly diagnosed patients were treated with MOPP/EBV/CAD hybrid. 27 (77%) cases of ALCL CD30+ and 8 (23%) cases of Hodgkin's-related (HR) lymphoma CD30+ were diagnosed. Extranodal disease was present in 22 cases (63%), and 8 patients (23%) had primary bone marrow involvement. Twenty-three complete remissions (CR) (66%), six partial remissions (PR) (17%) and s…

AdultMaleCD30+ HODGKINS-RELATED LYMPHOMACancer Researchmedicine.medical_specialtyPathologyAdolescentCD30CHOPGastroenterologyExtranodal Diseaseimmune system diseaseshemic and lymphatic diseasesInternal medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAnaplastic large-cell lymphomaAgedbusiness.industryNON-HODGKINS LYMPHOMAMiddle Agedmedicine.diseaseLymphomaNon-Hodgkin's lymphomaSurvival RateRegimenTreatment OutcomeOncologyLymphoma Large-Cell AnaplasticFemaleANAPLASTIC LARGE CELL LYMPHOMA (CD30+/KI-1+)AGGRESSIVE CHEMOTHERAPYANAPLASTIC LARGE CELL LYMPHOMA (CD30+/KI-1+); CD30+ HODGKINS-RELATED LYMPHOMA; NON-HODGKINS LYMPHOMA; AGGRESSIVE CHEMOTHERAPYbusinessFollow-Up StudiesEuropean Journal of Cancer
researchProduct

D2-40 negative pyogenic granuloma-like Kaposi's sarcoma: Diagnostic features and histogenetic hypothesis of an uncommon skin tumor in HIV-negative pa…

2015

Locate full-text(opens in a new window)|View at Publisher| Export | Download | Add to List | More... Pathology Research and Practice Volume 211, Issue 7, July 01, 2015, Pages 528-532 D2-40 negative pyogenic granuloma-like Kaposi's sarcoma: Diagnostic features and histogenetic hypothesis of an uncommon skin tumor in HIV-negative patients (Article) Cabibi, D.a, Giannone, A.G.a , Guarnotta, C.a, Schillaci, O.b, Franco, V.a a Department of Sciences for Promotion of Health and Mother and Child Care, University of Palermo, Palermo, Italy b Servizio di Anatomia Patologica, Dipartimento Oncologico di III livello, La Maddalena Casa di Cura di Alta Specialità, Palermo, Italy View references (20) Abst…

AdultMaleCD31Pathologymedicine.medical_specialtySkin NeoplasmsCD34Pyogenic granuloma-like Kaposi's sarcomaSettore MED/08 - Anatomia PatologicaVascular tumorPathology and Forensic MedicineD2-40Antibodies Monoclonal Murine-DerivedBiomarkers TumormedicineHHV8HumansGranuloma PyogenicSarcoma KaposiKaposi's sarcomaSkinRetrospective StudiesPodoplaninPyogenic granulomabusiness.industryKaposi's sarcomaCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryPyogenic granulomaLymphatic systemHerpesvirus 8 HumanFemaleSarcomaDifferential diagnosisbusinessImmunostainingPathology - Research and Practice
researchProduct

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey

2018

BACKGROUND: In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and therapeutic data from patients affected by haemophilia A (HA), haemophilia B (HB), von Willebrand’s disease (vWD) and other rare coagulation disorders. Here we present data from the 2016 annual survey. MATERIALS AND METHODS: Data are provided by the Italian Haemophilia Centres, on a voluntary basis. Information flows from every Centre to a web-based platform of the Italian Association of Haemophilia Centres, shared with the Italian National Institute of Health, in accordance with current privacy laws. Patients are classified by diagnosis, disease severity, age, gender and treatment-r…

AdultMaleCanadaAdolescentAdolescent Adult Aged Blood Coagulation Factors Canada Child Coagulation Protein Disorders Factor IX Factor VIII Female France HIV Infections Hemophilia A Hemophilia B Hepatitis CHumans Infant Infant Newborn Italy Male Middle Aged Prevalence Registries Surveys and Questionnaires United Kingdom von Willebrand DiseasesHIV InfectionsCoagulation Protein DisordersHemophilia AHemophilia BFactor IXhemic and lymphatic diseasesSurveys and QuestionnairesPrevalenceHumansRegistriesChildAgedFactor VIIIInfant NewbornInfantMiddle AgedHepatitis CBlood Coagulation FactorsUnited Kingdomvon Willebrand DiseasesItalyChild PreschoolFemaleOriginal ArticleFrance
researchProduct

Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

2014

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy and the fifth most common type of cancer in more developed regions of the world (1). Numerous NHL subtypes with distinct combinations of morphologic, immunophenotypic, genetic, and clinical features are currently recognized (2,3). The incidence of NHL subtypes varies substantially by age, sex, and race/ethnicity (4–7). However, the etiological implications of this biological, clinical, and epidemiological diversity are incompletely understood. The importance of investigating etiology by NHL subtype is clearly supported by research on immunosuppression, infections, and autoimmune diseases, which are the strongest and most e…

AdultMaleCancer ResearchAdolescentChronic lymphocytic leukemiaFollicular lymphomaComorbidityDiseaseNon-Hodgkin lymphoma (NHL)ArticleYoung AdultRisk Factorsimmune system diseasesOccupational Exposurehemic and lymphatic diseasesOdds RatiomedicineCluster AnalysisHumansRisk factorFamily historyLife StyleAgedAged 80 and overInternational Lymphoma Epidemiology Consortium (InterLymph)business.industryLymphoma Non-HodgkinAustraliaCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLymphomaEuropeOncologyCase-Control StudiesNorth AmericaImmunologyFemalebusinessJNCI Monographs
researchProduct

Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study.

2011

Background: Kaposi's sarcoma-associated herpes virus is associated with primary effusion lymphoma and multicentric Castleman's disease. Methods: Seropositivity to lytic and latent Kaposi's sarcoma herpes virus (KSHV) antigens were examined in 2083 lymphomas and 2013 controls from six European countries. Results: Antibodies against KSHV latent and lytic antigens were detectable in 4.5% and 3.4% of controls, respectively, and 3.6% of cases (P>0.05). The KSHV seropositivity was associated with splenic marginal zone lymphoma (SMZL) (odds ratio (OR)=4.11, 95% confidence interval (CI)=1.57–10.83) and multiple myeloma (OR=0.31, 95% CI=0.11–0.85). Conclusion: The KSHV is unlikely to contribute impo…

AdultMaleCancer ResearchAdolescentvirusesShort CommunicationserologylymphomaAntibodiesSerologyhuman herpes virus 8Young AdultHerpes virusAntigenhemic and lymphatic diseasesLymphoma Primary EffusionmedicineHumansChildKaposi's sarcomaAntigens ViralSarcoma KaposiAgedAged 80 and overbiologybusiness.industryCastleman DiseaseLymphoma Non-HodgkinCase-control studyInfant Newbornvirus diseasesInfantMiddle Agedmedicine.diseaseVirologyLymphomaEuropeOncologyLytic cycleKaposi's sarcoma-associated herpes virusCase-Control StudiesChild PreschoolImmunologyHerpesvirus 8 Humanbiology.proteinFemaleepidemiologyAntibodybusinessBritish journal of cancer
researchProduct

Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups

2009

B cell chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder with a variable clinical course. Patients with unmutated IgV(H) gene show a shorter progression-free and overall survival than patients with immunoglobulin heavy chain variable regions (IgV(H)) gene mutated. In addition, BCL6 mutations identify a subgroup of patients with high risk of progression. Gene expression was analysed in 36 early-stage patients using high-density microarrays. Around 150 genes differentially expressed were found according to IgV(H) mutations, whereas no difference was found according to BCL6 mutations. Functional profiling methods allowed us to distinguish KEGG and gene ontology terms showing…

AdultMaleCancer ResearchBCL6BiologyIgVHgenomichemic and lymphatic diseasesmedicineHumansKEGGGenemicroarraysAgedAged 80 and overRegulation of gene expressionGeneticsB-LymphocytesGene Expression ProfilingZAP70HematologyMiddle Agedmedicine.diseaseBCL6Leukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsGene Expression Regulation NeoplasticGene expression profilingLeukemiaOncologyTranscriptomicHealthMutationProto-Oncogene Proteins c-bcl-6Cancer researchImmunoglobulin heavy chainFemaleImmunoglobulin Heavy ChainsCLL
researchProduct

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.

2008

Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen…

AdultMaleCancer ResearchDNA ComplementaryT-LymphocytesAntigen-Presenting CellsEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyAntigenhemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCytotoxic T cellHumansIn Situ Hybridization FluorescenceReverse Transcriptase Polymerase Chain ReactionHematologyNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseTransplantationHaematopoiesismedicine.anatomical_structureOncologyImmunologyBone marrowStem cellChronic myelogenous leukemiaLeukemia
researchProduct

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3…

2008

Activating mutations of FLT3 are found in approximately one-third of acute myeloid leukemia (AML)-cases and are considered to represent an attractive therapeutic target. In this study, we report that the hydroxystyryl-acrylonitrile compound LS104 inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells in vitro. Immunoblot and phosphoprotein-FACS analysis demonstrated inhibiton of phosphorylation of FLT3-ITD and of its downstream targets. In pharmacokinetic studies, a rapid and dose dependent cellular uptake of LS104 lasting up to 11h could be demonstrated. Combination of LS104 with chemotherapeutic agents markedly enhanced cytotoxic effects. Recently, a…

AdultMaleCancer ResearchDaunorubicinmedicine.drug_classBlotting WesternFluorescent Antibody TechniqueApoptosisPharmacologyReceptor tyrosine kinaseTyrosine-kinase inhibitorStyrenesColony-Forming Units AssayMiceBone Marrowhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedCD135AnimalsHumansPoint MutationTissue DistributionAgedCell ProliferationAged 80 and overbiologyAcrylonitrileDaunorubicinCytarabineMyeloid leukemiaCell DifferentiationHematologyMiddle Agedmedicine.diseaseLeukemiaLeukemia Myeloid AcuteOncologyfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3Cytarabinebiology.proteinCancer researchDrug Therapy CombinationFemalemedicine.drugSignal TransductionLeukemia research
researchProduct

Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis.

1998

BACKGROUND Expression of nm23 has been shown to be inversely correlated with the metastatic potential of several human cancers. In the current study, the expression and prognostic impact of nm23 was immunohistochemically studied in 413 curatively resected gastric carcinomas. METHODS Tumor sections of the 413 gastric carcinomas were stained with a polyclonal antibody that was raised against the nm23-H1/NDP kinase A, which is identical to the nm23-H1 gene product. RESULTS Expression of nm23 was detected in 84.5% (n = 349) of all tumors, in the majority of cases (71.2%) causing a homogeneous staining reaction in more than 75% of tumor cells. Expression of nm23 was positively correlated with th…

AdultMaleCancer ResearchMetastasisAntigens NeoplasmStomach NeoplasmsLymphatic vesselBiomarkers TumorMedicineHumansLymph nodeAgedMonomeric GTP-Binding ProteinsAged 80 and overbusiness.industryStomachCarcinomaCancerMiddle AgedNM23 Nucleoside Diphosphate Kinasesmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyTumor progressionNucleoside-Diphosphate KinaseCancer researchAdenocarcinomaImmunohistochemistryFemalebusinessCarcinoma Signet Ring CellTranscription FactorsCancer
researchProduct